Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

A study shows reduced-dose apixaban effectively prevents recurrent blood clots in cancer patients, lowering bleeding risks ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant ... a 1:1 ratio to receive oral apixaban at a reduced (2.5 ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

It has a plasma elimination half-life of 12 hours and has been ... without the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination pathways, and its ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

The aim of the API-CAT trial was to assess whether the lower dose of apixaban was comparable to the full dose in preventing VTE recurrence in patients with active cancer who had completed at least ...

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...